First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

NCT07216066 | Recruiting Phase 1

• 2 other identifiers: ALN-SNCA-PD-24822025-521431-37-00
• Study Type: interventional
• Target: 46
• Locations: 2 countries
• Sites: 2

Brief Summary

This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, especially those due to the harmful build-up of a protein called α-synuclein. The aim of the study is to see if the study drug is safe and tolerated well enough to continue testing it in future studies and what side effects may happen from taking the study drug. The study is looking at several other research questions, including:

• Whether the study drug can lower the level of α-synuclein protein in the Cerebrospinal Fluid (also referred to as "CSF", the fluid that surrounds the brain and spinal cord)
• How much study drug is in the blood, urine, and CSF at different times
• Compatible research to better understand the study drug (ALN-SNCA) and Parkinson's disease, including (but not limited to), whether the study drug can slow down the progression of Parkinson's disease symptoms

Conditions

Parkinsons Disease

Keywords

Early Parkinsons disease; Motor and non-motor brain systems; Bradykinesia plus; Resting tremor; Rigidity; Postural instability; Cognitive impairment; Mood disorders; Sleep disturbances; Autonomic dysfunction

Outcome Measures

Primary Outcomes (2)

• Occurrence of Treatment-Emergent Adverse Events (TEAEs)

  Through Week 80

• Severity of TEAEs

  Through Week 80

Secondary Outcomes (8)

• Concentration of alpha (a)-synuclein protein in CSF

  Through Week 48

• Change from baseline in concentration of a-synuclein protein in CSF

  Through Week 48

• Concentration of ALN-SNCA in plasma

  Through Week 48

• Concentration of major metabolites in plasma

  Through Week 48

• Concentration of ALN-SNCA in CSF

  Through Week 48

Study Arms (2)

ALN-SNCA Dose Escalation

EXPERIMENTAL

Drug: ALN-SNCA

Matching Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

ALN-SNCA DRUG

Administered per the protocol

ALN-SNCA Dose Escalation

Placebo DRUG

Administered per the protocol

Matching Placebo

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of Parkinson's disease according to the Movement Disorder Society (MDS) criteria, as assessed by the investigator, with bradykinesia plus at least one of the other cardinal signs of Parkinson's disease (resting tremor, rigidity), without any other known or suspected cause of Parkinsonism
• A diagnosis of Parkinson's disease for 4 years or less at the screening visit
• Participant must meet one of the following criteria:
• Currently not receiving any standard-of-care (SoC) therapy for Parkinson's disease, has not been on oral dopaminergic therapy (ie, levodopa, dopamine agonists, or Monoamine Oxidase B \[MAO-B\] inhibitors) prior to dosing, and is not anticipated to require SoC therapy for Parkinson's disease within approximately 6 months following dosing, or
• Has been on a stable regimen of oral dopaminergic therapy for at least 3 months prior to dosing and is not anticipated to require dose adjustments within approximately 6 months following dosing
• BMI ≤35 kg/m\^2 at time of screening visit

You may not qualify if:

• Medical history indicating a Parkinsonian syndrome other than Parkinson's disease, as defined in the protocol
• Clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding Parkinson's disease) that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant during study participation
• Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as defined in the protocol
• Any contraindications to undergo a brain Magnetic Resonance Imaging (MRI)
• An established allergy or intolerance to lidocaine anesthetic, as defined in the protocol
• History of intolerance to Intrathecal (IT) injection(s)
• Current history of bleeding diatheses that would increase risk of bleeding upon LP
• Has undergone gene therapy, cell therapy or surgical treatment, including deep brain stimulation, for Parkinson's disease

Sponsors & Collaborators

• Regeneron Pharmaceuticals: lead

Study Sites (2)

Montreal Neurological Institute and Hospital

Montreal, Quebec, H3A 2B4, Canada

RECRUITING

Center for Human Drug Research

Leiden, South Holland, 2333 CL, Netherlands

RECRUITING

MeSH Terms

Conditions

Parkinson Disease; Tremor; Muscle Rigidity; Cognitive Dysfunction; Mood Disorders; Parasomnias; Primary Dysautonomias

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Dyskinesias; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Muscular Diseases; Musculoskeletal Diseases; Muscle Hypertonia; Neuromuscular Manifestations; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Sleep Wake Disorders; Autonomic Nervous System Diseases

Study Officials

• Clinical Trial Management

  Regeneron Pharmaceuticals

  STUDY DIRECTOR

Central Study Contacts

Clinical Trials Administrator

CONTACT

844-734-6643; clinicaltrials@regeneron.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 9, 2025
• First Posted: October 14, 2025
• Study Start: December 5, 2025
• Primary Completion (Estimated): June 7, 2029
• Study Completion (Estimated): June 7, 2029
• Last Updated: April 14, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: When Regeneron has: * received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development * made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) * the legal authority to share the data, and * ensured the ability to protect participant privacy
• Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Locations

NL (1); CA (1)